SCHEMBL25320720

SCHEMBL25320720

COC(=O)c1ccc([N+](=O)[O-])c(F)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.43
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 4/20 0.41
VCAM1 P19320 1/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MAPK1 P28482 2/20 0.40
ALDH1A1 P00352 4/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ABCC4 O15439 1/20 0.39
PLIN1 O60240 1/20 0.39
CACNA1F O60840 1/20 0.39
GMNN O75496 1/20 0.39
KCNK2 O95069 1/20 0.39
ABCB11 O95342 1/20 0.39
GSR P00390 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31413102 1.00 SIRT6 (0.43) SIRT6KMT2AMEN1MAPTVCAM1
SCHEMBL11388218 0.84 ALDH1A1 (0.42) SIRT6KMT2AMEN1MAPTVCAM1
SCHEMBL29210647 0.83 CYP1A2 (0.53) KMT2AMEN1MAPTNPSR1MAPK1
SCHEMBL4934807 0.83 MAPT (0.41) SIRT6KMT2AMEN1MAPTVCAM1
SCHEMBL29556542 0.83 MAPT (0.42) SIRT6KMT2AMEN1MAPTVCAM1
SCHEMBL4652551 0.83 MYC (0.44) SIRT6KMT2AMEN1VCAM1MAPK1
SCHEMBL20266533 0.83 MAPT (0.42) SIRT6KMT2AMEN1MAPTVCAM1
SCHEMBL20515306 0.80 ERN1 (0.42) SIRT6KMT2AMEN1MAPTVCAM1
SCHEMBL319297 0.80 KMT2A (0.35) SIRT6KMT2AMEN1MAPTVCAM1
SCHEMBL25321307 0.80 CASP6 (0.46) MAPTALDH1A1LMNAKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 EP disclosed
US-20240360109-A1 CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2024-10-31 US disclosed
EP-4382525-A1 CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-06-12 EP disclosed
WO-2023138684-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO , INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR SIRT6 818/4885KMT2A 3670/4885MEN1 450/4885
US-20240360109-A1 CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF CYP51A1, FAR1, CYP46A1 SIRT6 2142/4885KMT2A 4210/4885MEN1 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.